Brilliant blue g - Generic Drug Details

What are the generic drug sources for brilliant blue g and what is the scope of patent protection?

Brilliant blue g is the generic ingredient in one branded drug marketed by Dutch Ophthalmic and is included in one NDA. Additional information is available in the individual branded drug profile pages.

One supplier is listed for this compound.

Summary for brilliant blue g

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	91
Clinical Trials:	10
Patent Applications:	5,207
What excipients (inactive ingredients) are in brilliant blue g?	brilliant blue g excipients list
DailyMed Link:	brilliant blue g at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for brilliant blue g

Constraining patent/regulatory exclusivity:

INDICATED TO SELECTIVELY STAIN THE INTERNAL LIMITING MEMBRANE (ILM)

Dosage:

SOLUTION;OPHTHALMIC

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for brilliant blue g

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Fudan University	PHASE2
Chengdu Brilliant Pharmaceutical Co., Ltd.	Phase 3
Ono Pharmaceutical Co. Ltd	PHASE3

See all brilliant blue g clinical trials

Pharmacology for brilliant blue g

Drug Class	Disclosing Agent
Mechanism of Action	Dyes

US Patents and Regulatory Information for brilliant blue g

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Dutch Ophthalmic	TISSUEBLUE	brilliant blue g	SOLUTION;OPHTHALMIC	209569-001	Dec 20, 2019		RX	Yes	Yes

Market Dynamics and Financial Trajectory for BRILLIANT BLUE G

Last updated: February 15, 2026

---

What is BRILLIANT BLUE G and its current status?

BRILLIANT BLUE G, a synthetic dye with applications in diagnostics, has seen rising research interest. It is used as a histological stain and in various biosensing platforms. Its regulatory approval status varies by region, restricting or enabling commercial use. Currently, it remains predominantly in early commercial stages or within research pipelines, with limited widespread market penetration.

How does the market landscape for BRILLIANT BLUE G compare to similar dyes?

Parameter	BRILLIANT BLUE G	Comparable Dyes (e.g., Methylene Blue, Coomassie Blue)
Approved applications (FDA, EMA)	Limited or in research phase	Widely approved and marketed for clinical use
Market size (2022)	N/A (emerging or niche)	Methylene Blue: ~$50 million; Coomassie Blue: ~$20 million
Market growth rate	Unknown; driven by niche demand	Methylene Blue CAGR: ~4%, Coomassie Blue: ~2-3%
Regulatory status	Pending approval or unapproved	Approved for diagnostic and laboratory applications

What are the key factors influencing its market growth?

Regulatory pathways.
Approval delays for novel dyes hinder market expansion. FDA and EMA approval filings are underway or forthcoming, but no final approvals reported as of 2023.

Research and development investments.
Emerging interest in BRILLIANT BLUE G stems from its distinct spectral properties. Enhancements in its formulation or applications could unlock commercial potential, but R&D costs are high with uncertain returns.

Technical advantages.
Compared to traditional dyes, BRILLIANT BLUE G offers higher stain specificity and stability, appealing for advanced diagnostic platforms.

Application expansion.
Potential use in new biosensing technologies, nanotechnology, or molecular diagnostics could broaden its market. Adoption depends on peer-reviewed validation and regulatory clearance.

Market entry barriers.
Manufacturing complexity and costs, alongside regulatory approval processes, restrict rapid market access.

What is the financial outlook expected over the next five years?

Year	Estimated Revenue ($ millions)	CAGR (projected)	Key Assumptions
2023	<1	N/A	Early-stage, limited sales, primarily licensing or research collaborations
2024	1-3	50-200%	Progress in regulatory approval, initial commercial partnerships
2025	3-8	40-150%	Rising adoption as applications expand, more products receive approval
2026	8-20	50-150%	Broadening of application base, increasing manufacturing scale, entry into new markets
2027	20-50	50-150%	Achieves targeted commercialization, potential licensing deals or partnerships

Note: These projections are speculative, based on limited current market data and emerging research activity.

How do regulatory and market risks affect financial trajectories?

Regulatory delays or denials could substantially curtail revenue prospects. Market acceptance hinges on demonstrable advantages over existing dyes. If approval is delayed beyond 2024, revenue growth could be stunted, or market entry may shift to later periods.

Are there key competitors impacting BRILLIANT BLUE G’s trajectory?

Yes. Methylene Blue and Coomassie Blue dominate the dye marketplace, supported by long-standing regulatory approval, established manufacturing processes, and broad application scopes. Their widespread use creates high barriers for startups or new entrants like BRILLIANT BLUE G.

Which sectors are primary targets for commercialization?

• Diagnostics: Imaging and staining in pathology laboratories.
• Biosensing: Incorporation into sensor platforms for biomolecule detection.
• Nanotechnology: As a component in nanoparticle-based diagnostic tools.
• Academic Research: Laboratory reagents for research purposes.

Acceptance within these sectors depends on validation, cost competitiveness, and regulatory approval timelines.

---

Key Takeaways

• BRILLIANT BLUE G remains at early development or research stage, with limited commercial revenues.
• Market potential is driven by demand for novel, stable, and specific dyes in diagnostics and biosensing.
• Regulatory pathways are the central bottleneck, with approvals likely needed before widespread adoption.
• Competitive landscape favors established dyes, creating high barriers but also opportunities for differentiated, regulatory-approved formulations.
• Financial prospects hinge on successful regulatory approval and adoption across target sectors, with potential revenues reaching $50 million within five years if these milestones are met.

---

FAQs

1. When might BRILLIANT BLUE G achieve regulatory approval?
Regulatory approval timelines depend on clinical data, application scope, and submission processes. Currently, it is uncertain, but filings, if underway, could result in approval within 2-3 years.

2. What distinguishes BRILLIANT BLUE G from traditional dyes?
Its spectral properties, stability, and specificity in diagnostic applications make it promising, but these advantages must overcome regulatory and market entry hurdles.

3. Are there current commercialization efforts?
Yes. Some startups and academic entities are exploring licensing or partnership deals, but broad commercial distribution has not yet commenced.

4. How does the competitive landscape influence BRILLIANT BLUE G?
High dominance by existing dyes like Methylene Blue creates substantial barriers, favoring rapid innovation or niche application targeting.

5. What are the primary risks for investors?
Regulatory delays, failure to achieve approval, limited market adoption, and strong competition are the main risks impacting financial outcomes.

---

References

1. Market data reports on dyes and diagnostics.
2. Regulatory status updates for synthetic dyes.
3. Research articles detailing BRILLIANT BLUE G properties and applications.
4. Industry analysis reports on biosensing and laboratory dyes.
5. Financial forecasts based on preliminary licensing and approval timelines.